+ Product Pathways
- All Targets
- Angiogenesis/Tyrosine Kinase
- Cell Cycle/Checkpoint
- HDAC
- Apoptosis
- PARP
- Aurora/Ksp
- MAPK
- PI3K/Akt/mTOR
- Hormone
- Integrase/CCR5
- Proteases/HSP90/HSP70
- Wnt/Hedgehog/Notch
- Jak/Stat
- Ca/cAMP/Lipid Signaling
- Neuro Signaling
- TGF-beta/Smad Signaling
- GPCR
- Ion channel
- Cytochrome P450
- Others
- Cancer
- Infection
- Endocrinology
- Metabolic Disease
- Inflammation
- Immunology
- Neurological Disease
- Cardiovascular Disease
Vascular endothelial growth factor receptor-Platelet derived growth factor receptor
| Cat.No. | Product Name | Feedback | Added |
|---|---|---|---|
| S1486 | AEE788 | Sep 2010 | |
| AEE788 is a novel multitargeted human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1. | |||
| S2221 | Apatinib (YN968D1) | Apr 2011 | |
| Apatinib (YN968D1) is a small-molecule selective multitargeted tyrosine kinase inhibitor with an IC50 of 2.43 nM for the inhibition of VEGFR2. | |||
| S1207 | AV-951(Tivozanib) | May 2010 | |
| AV-951 (Tivozanib) is a potent and selective VEGFR inhibitor to all three VEGF receptors, VEGFR-1, -2 and -3 with IC50 of 0.21 nM, 0.16 nM and 0.24 nM, respectively. | |||
| S1005 | Axitinib | Apr 2009 | |
| Axitinib is a receptor kinase inhibitor with IC50 of 0.1 nmol (VEGFR-1), 0.2 nmol (VEGFR-2), 0.1–0.3 nmol (VEGFR-3), 1.6 nmol (PDGFR-β) and 1.7 nmol (c-KIT). | |||
| S1010 | BIBF1120 (Vargatef) | Apr 2009 | |
| BIBF1120 (Vargatef) is a potent VEGF receptor (VEGFR), PDGFR and FGFR kinase inhibitor to VEGFR1, VEGFR2,VEGFR3 with IC50 of 34, 13 and 13 nM, respectively. | |||
| S2201 | BMS 794833 | Jan 2011 | |
| BMS794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol. | |||
| S1084 | Brivanib (BMS-540215) | Jul 2009 | |
| Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM. | |||
| S1138 | Brivanib alaninate(BMS-582664) | Jan 2010 | |
| A multiple inhibitor of VEGFR( IC50 of VEGFR-2(25 nM), VEGFR-1 (380nM), VEGFR-3 (10 nM)); FGFR (FGFR-1 (IC50=148 nM), FGFR-2 (IC50 =125 nM), and FGFR-3 (IC50 = 68 nM))tyrosine kinases | |||
| S1017 | Cediranib (AZD2171) | Apr 2009 | |
| Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor to VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively. | |||
| S2730 | Crenolanib (CP-868569) | Dec 2011 | |
| Crenolanib (CP-868569) is a highly selective and potent PDGFR-α inhibitor with IC50 of 0.9 and 1.8 nM against PDGFRα and PDGFRβ, respectively. | |||
| S1171 | CYC116 | Apr 2010 | |
| CYC116 is an Aurora kinase/VEGFR2 inhibitor | |||
| S1018 | Dovitinib (TKI258) | Apr 2009 | |
| Dovitinib (TKI258) is a highly potent, novel multitargeted growth factor receptor kinase inhibitor with IC50 of 1, 2, 5, 10, 8, 27, 36 nM for FLT3, c-KIT, FGFR, VEGFR1/2/3, PDGFRß and CSF-1R, respectively. | |||
| S1164 | E7080 | Feb 2010 | |
| Inhibitor of VEGF-R3 tyrosine kinase (IC50=5.2 nM) and VEGF-R2 tyrosine kinase (IC50=4.0 nM) | |||
| S1111 | Foretinib (GSK1363089, XL880) | Sep 2009 | |
| Foretinib (GSK1363089, XL880) is a novel MET and VEGFR2/KDR kinases inhibitor with an IC50 of 0.4 and 0.8 nM for MET and KDR, respectively. | |||
| S2475 | Imatinib (Gleevec) | Feb 2011 | |
| Imatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor. | |||
| S1026 | Imatinib Mesylate | Apr 2009 | |
| Imatinib Mesylate is a multitargeted c-kit, PDGF-R and c-ABL inhibitor with IC50 of 3.9 and 2.9 μM for the inhibition of T-cell proliferation stimulated by DCs and PHA, respectively. | |||
| S1363 | Ki8751 | Jun 2010 | |
| Ki8751 is a potent, selective VEGFR-2 tyrosine kinase inhibitor with IC50 of 0.9 nM, 40, 67, 170 nM for VEGF-2, c-Kit, PDGFRα and FGFR-2, respectively. | |||
| S1557 | KRN 633 | Nov 2010 | |
| KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor with IC50 of 170 nM, 160 nM, and 125 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. | |||
| S1003 | Linifanib (ABT-869) | Apr 2009 | |
| Linifanib (ABT-869) is a structurally novel, potent RTK and VEGF and PDGF receptor families inhibitor to human endothelial cells, PDGFR-β, KDR, and CSF-1R, with IC50 of 0.2, 2, 4, and 7 nM, respectively. | |||
| S1064 | Masitinib | May 2009 | |
| Masitinib also known as Masivet, AB1010 is a tyrosine kinase, c-Kit, PDGFR, FGFR3, the FAK pathway inhibitor with IC50 of 150 ± 80, 200 ± 40 nM. | |||
| S1361 | MGCD-265 | Jun 2010 | |
| MGCD-265 is a multi-targeted kinase inhibitor, which targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases. | |||
| S1032 | Motesanib (AMG-706) | Apr 2009 | |
| Motesanib (AMG-706) is a multiple inhibitor of VEGFR1/2/3(IC50: 2 ηM /3 ηM /6 ηM),PDGFR (84ηM), kit (8ηM), and Ret (59ηM)receptors | |||
| S1244 | MP-470 | May 2010 | |
| MP-470 is a multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Met, c-Kit, PDGFRalpha, Flt3, and c-Ret and with an IC50 of median 5 μM. | |||
| S2202 | NVP-BHG712 | Mar 2011 | |
| NVP-BHG712 is a small molecule specific EphB4, VEGFR2, c-raf, c-src and c-Abl kinase inhibitor with ED50 of 25 nM, 4.2, 0.4, 1.3 and 1.7μM, respectively. | |||
| S1220 | OSI-930 | May 2010 | |
| OSI-930 is an inhibitor of the receptor tyrosine kinases c-Kit (IC50:9.5nM) and VEGFR-2 (IC50:10.1nM). | |||
| S1035 | Pazopanib | Apr 2009 | |
| Pazopanib is a VEGFR inhibitor, IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3. | |||
| S1264 | PD173074 | Jun 2010 | |
| PD173074 is a potent ATP-competitive, reversible FGFR and VEGFR inhibitor with IC50 of 5, 21.5 and ~100 nM for FGFR3, FGFR1 and VEGFR2, respectively. | |||
| S1490 | Ponatinib (AP24534) | Sep 2010 | |
| Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN. | |||
| S2622 | PP121 | Jun 2011 | |
| PP121 is a multitargeted dual receptor tyrosine kinases inhibitor with IC50 of 0.052, 1.4, 0.15, 1.1, 0.06, 0.01and 0.002 μM for p110α, p110β, p110δ, p110γ, DNA-PK, mTOR and PDGFR, respectively. | |||
| S2161 | RAF265 (CHIR-265) | Jan 2011 | |
| RAF265 (CHIR-265) is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM. | |||
| S2200 | Raf265 derivative | Mar 2011 | |
| Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM. | |||
| S1178 | Regorafenib (BAY 73-4506) | Apr 2010 | |
| Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. | |||
| S1040 | Sorafenib (Nexavar) | May 2009 | |
| Sorafenib (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. | |||
| S1042 | Sunitinib (Sutent) | May 2009 | |
| Sunitinib Malate (Sutent) is a multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor with Ki of 0.009 and 0.008 µM for Flk-1 and PDGFR. | |||
| S2231 | Telatinib (BAY 57-9352) | Apr 2011 | |
| Telatinib (BAY 57-9352) is an orally available, potent multitargeted VEGFR-2, VEGFR-3, PDGFR-β and c-Kit tyrosine kinases inhibitor with an IC50 of 19 nM for the inhibition of VEGFR-2 autophosphorylation. | |||
| S1470 | TSU-68 (SU6668) | Aug 2010 | |
| TSU-68 (SU6668)is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 µM, 8 nM and 1.2 µM for VEGF-R1, PDGF-Rβ and FGF-R1, respectively. | |||
| S1046 | Vandetanib (Zactima) | Apr 2009 | |
| Vandetanib (Zactima) is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor with IC50 of 60, 90, 40 nM for HUVEC proliferation, PC-9 cells and tyrosine kinase activity, respectively. | |||
| S1101 | Vatalanib (PTK787) | Aug 2009 | |
| Vatalanib (PTK787) is a novel VEGFR and c-Kit tyrosine kinases and angiogenesis inhibitor with IC50 of 0.037, 0.077, 0.27 and 0.73 μM for KDR, Flt-1, Flk and c-Kit, respectively. | |||
| S1119 | XL184 (Cabozantinib) | Sep 2009 | |
| XL184 (Cabozantinib) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. | |||
Buy Now / Print Quote
Find Multiple Products by Catalog Number
Customer's Feedback
| Dongfeng Chen, The Rausing Lab |
| "Your product U0126(Cat.NO S1102) works well in our experiments. I hope I can get more excellent products from your company in future." |
| R.B. Cambridge |
| "I have used the chemical that I bought from you(Selleck,PTC-124) and it worked well.So we will eventually be ordering more." |
| Zhenghe John Wang Assistant Professor, Case Western Reserve University |
| "We have purchased LBH-589, Saha and MS-275 from you and they all worked well." |
| Jenny Sun |
| "We used the LBH-589 in our experiments. The compound is easy to use with excellent reproducibility." |
| Yu Wang, Harvard University |
| "The GDC0449 compound worked very well. The results in my hands are equally good as what's been published. Thanks for this great resource for our research." |
| Dung-Fang Lee |
| "Based on our preliminary data, I found MLN8237 and VX-680 have good effects in inhibiting Aurka-maintaining ESC self-renewal in mouse ES cells." |
Latest Catalog
| May 2010 Selleck Latest Catalog | ![]() |

